News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ultragenyx Pharmaceuticals Announces First Patient Enrolled In Phase 2 Study Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome


3/11/2014 8:03:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novato, CA, March 11, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient enrolled in the Phase 2 study of triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS), at Columbia University. Glut1 DS, also known as De Vivo disease, is a rare, severely debilitating disease characterized by seizures, developmental delay, and movement disorder. - See more at: http://www.globenewswire.com/news-release/2014/03/11/617396/10072064/en/Ultragenyx-Announces-First-Patient-Enrolled-in-Phase-2-Study-of-Triheptanoin-in-Glucose-Transporter-Type-1-Deficiency-Syndrome.html#sthash.ORaFUasA.dpuf

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES